India

Cadila Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate

Lead Product(s): Calcipotriol,Betamethasone

Therapeutic Area: Dermatology Product Name: AKP-02

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Lipidor AB

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 07, 2020

Details:

Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spray-based AKVANO technology.

SPARC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases

Lead Product(s): SCD-044

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

Deal Size: $145.0 million Upfront Cash: $20.0 million

Deal Type: Licensing Agreement May 29, 2020

Details:

Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

Aurigene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Aurigene announces dose administration in first patient study for phase II study of psoriasis

Lead Product(s): AUR101

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Cadila Pharmaceuticals

Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate

SPARC

SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases

Aurigene

Aurigene announces dose administration in first patient study for phase II study of psoriasis